Seroconversion and adverse reaction of live-attenuated (OKA strain) varicella vaccine

  • Yulchair Ramli
  • Sri Rezeki H A
  • Arwin P Akib
Keywords: varicella vaccine, seroconversion, adverse reaction

Abstract

Background Live-attenuated varicella vaccine was used to pre-
vent Shingle disease.
Objective The aim of this study was to find out seroconversion
rate and safety of this vaccine.
Methods An open clinical trial was conducted on 313 children at
Cipto Mangunkusumo Hospital, Jakarta between March and Octo-
ber 1998. The data were analyzed to distribution frequency and
tables.
Results Only 43 out of 356 (12.1%) children had positive
antivaricella antibody before vaccination. Seroconversion exami-
nation by indirect immunoflouresence method was done only on
randomly 150 of 313 (50%) children due to financial limitation. It
was found that 99.3% of patients had positive seroconversion.
Among 298 children who were followed, the nature of symptom of
adverse reaction was mostly general than local. Only one patient
had local symptom after vaccination that appeared within 7 days
of the follow up period.
Conclusion Varicella vaccine (OKA strain) gives high
seroconversion rate with minimal adverse events

Author Biographies

Yulchair Ramli
Department of Child Health, Medical School, University of
Indonesia, Jakarta.
Sri Rezeki H A
Department of Child Health, Medical School, University of
Indonesia, Jakarta.
Arwin P Akib
Department of Child Health, Medical School, University of
Indonesia, Jakarta.

References

1. Preblud SR, Orenstein WA, Bart KJ. Varicella: clini-
cal manifestation, epidemiology and health impact in
children. Pediatr Inf Dis 1984;3:505-9.
2. Taylor-Wiedeman J, Yamashita K, Miyamura K,
Yamazaki S. Varicella-zoster virus prevalence in Japan:
no significant change in decade. Jpn J Med Sci Bio
1989;42:1-11.
3. Venkitaraman AR, Seigneurin JM, Lenoir GM, John
TJ. Infection due to the human herpes viruses in south-
ern India: a seroepidemiological survey. Int J Epidemiol
1986;15:561-6.
4. Ooi PL, Goh KT, Dorasingham S, Ling AE. Prevalence
of varicella-zoster virus infection in Singapore. South-
east Asean J Trop Med Pub Health 1992;23:22-5.
5. Alvarez y Munoz MT, Torres J, Damasio-Santana L,
Gomez A, Fernandez-Quintanilla G, Tapia-Conyer R,
et al. Susceptibility to varicella-zoster infection in in-
dividual 1 to 29 years of age in Mexico. Arch Med Res
1999;30:60-3.
6. Juffrie M, Graham RR, Tan RI, Widjaja S, Muhjadi S,
Well J, et al. Seroprevalence of hepatitis A virus and
varicella zoster antibodies in a Javanese community
(Yogyakarta, Indonesia). Southeast Asean J Trop Med
Public Health 2000;31:21-4
7. Chartrand SA. Varicella vaccine. Pediatr Clin North
Am 2000;47:1-16.
8. Takahashi M. The varicella vaccine. Vaccine develop-
ment. Infect Dis Clin North Am 1996;10:1-12.
9. Zoulek G. Laboratory markers of immunity to vari-
cella-zoster virus. Postgrad Med J 1985;61 Suppl
4:47-52.
10. Kubo T, Rai SK, Nakanishi M, Yamano T.
Seroepidemiological study of herpes viruses in Nepal.
Southeast Asean J Trop Med Public Health
1991;22:323-5.
11. Zhou T, Wang J, Qiu P. Investigation on sera preva-
lence rate of varicella and immunogenicity of varicella
vaccine in healthy children. Chinese J Epidemiol
1998;19:271-3.
12. Mandal BK, Mukherjee PP, Murphy C, Mukherjee R,
Naik T. Adult susceptibility to varicella in the tropics
is a rural phenomenon due to the lack of previous ex-
posure. J Infect Dis 1998;178 Suppl 1:S52-4.
13. Takahashi M. Clinical overview of varicella vaccine:
development and early studies. Pediatrics 1986;78
Suppl 1:736-41.
14. Takahashi M, Kamiya H, Baba K. Clinical experience
with Oka live varicella vaccine in Japan. Postgrad Med
J 1985;61:61.
15. Gershon AA. Viral vaccines of the future. Pediatr Clin
North Am 1990;37:689-707.
16. Andre FE. Worldwide experience with the OKA-strain
live varicella vaccine. Postgrad Med J 1985;61 Suppl
4:113-20.
17. White CJ, Kuter BJ, Hildebrand CS, Isganitis KL,
Matthews H, Miller WJ, et al. Varicella vaccine
(VARIVAX) in healthy children and adolescents: re-
sult from clinical trials, 1987 to 1989. Pediatrics
1991;87:604-10.
18. Meurice F, De Bouver J, Vandevoorde D, Woods S,
Bogaerts H. Immunogenicity and safety of a live at-
tenuated varicella vaccine (OKA/SB Bio) in healthy
children. J Infect Dis 1996;174 Suppl 3:S324-9.
19. Ozaki T, Nishimura N, Kajita Y. Experience with live
attenuated varicella vaccine (OKA strain) in healthy
Japanese subjetcs; 10-year survey at pediatric clinic.
Vaccine 2000;18:2375-80.
20. Watson BM, Laufer DS, Kuter BJ, Staehle B, White
CJ. Safety and immunogenicity of a combined live at-
tenuated measles, mumps, rubella, and varicella vac-
cine (MMR II V) in healthy children. J Infect Dis
1996;173:731-4.
Published
2016-09-26
How to Cite
1.
Ramli Y, A SR, Akib A. Seroconversion and adverse reaction of live-attenuated (OKA strain) varicella vaccine. PI [Internet]. 26Sep.2016 [cited 29Mar.2024];43(5):171-. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/688
Received 2016-09-24
Accepted 2016-09-24
Published 2016-09-26